

REVIEW OF DECISIONS

BOARD MEETING

28-29 November 2018, Geneva



Reach every child

www.gavi.org

Decision 1: Financial Update, including forecast (1/2)

The Gavi Alliance Board:

- a) **Approved** the Financial Forecast for the period 2016-2020 as set out in Section B of Doc 05.
- b) **Took note** of the indicative Financial Projections for the 2021-2025 period, as set out in Section B of Doc 05, which is based on existing and anticipated programmatic commitments but is dependent on Board approval of the next Gavi Strategy, and any potential programmatic and policy shifts for the given period.

Decision 1: Financial Update, including forecast (2/2)

- c) **Authorised** the Gavi Secretariat to allot funding in 2019 for new programmes and for the continuation and adjustment of funding to existing programmes, in accordance with the Programme Funding Policy. In making such allotment decisions, the Secretariat will take into consideration the development of the strategy for the 2021-2025 period.
- d) **Approved** within the overall Partners Engagement Framework: an amount of US\$ 0.7 million in 2019 for UNICEF Supply Division for fees to implement cold chain equipment, in addition to the US\$ 3.6 million already approved for 2019 by the Board in November 2017.

Decision 2: Risk and Assurance Report

The Gavi Alliance Board:

Approved the Risk & Assurance Report 2018 attached as Annex A to Doc 06a.

Decision 3: IFFIm and CEPI

The Gavi Alliance Board considered Gavi supporting the Coalition for Epidemic Preparedness Innovation (CEPI), subject to funds being made available by the Kingdom of Norway and disbursed via IFFIm (the CEPI Arrangement), and:

- a) **Approved** the CEPI Arrangement;
- b) **Noted** that the CEPI Arrangement will be considered as a Gavi Non Country-Specific Programme consistent with IFFIm's requirements;
- c) **Noted** further that the CEPI Arrangement does not constitute a precedent for Gavi to fund research and development; and
- d) **Requested** that the Secretariat puts in place the necessary measures to implement the CEPI Arrangement with IFFIm, CEPI and the Government of Norway, taking into account the guidance provided by Gavi's Audit and Finance Committee.

Decision 4: Vaccine Investment Strategy (1/5)

The Gavi Alliance Board, subject to the availability of funding for the 2021-2025 period following Gavi's replenishment for that period and subject to alignment with the final parameter setting for Gavi 5.0 at the June 2019 Board meeting:

- a) **Approved** support for diphtheria, tetanus & pertussis-containing (D, T & P) vaccines (tetanus-diphtheria, diphtheria-tetanus-whole-cell pertussis, pentavalent) to be used as booster doses beginning in 2021 by:
- i. Providing funding to establish platforms as catalytic support for the introduction of each D, T, & P-containing vaccine as a booster dose;
 - ii. Supporting the procurement of above mentioned D, T, & P-containing booster vaccines in line with the co-financing policy.

Decision 4: Vaccine Investment Strategy (2/5)

- b) **Approved** support for hepatitis B birth dose beginning in 2021 by:
- i. Providing funding to establish platforms as catalytic support for the introduction of hepatitis B vaccine administered at birth
 - ii. Supporting the procurement of hepatitis B vaccines in standard vial presentations and in line with the co-financing policy.
- c) **Approved**, in principle, an expansion of the existing meningococcal programme to support a targeted approach that includes, in principle, support for ACW-containing multivalent meningococcal conjugate vaccines, contingent on the availability of a licensed product, outcomes of regulatory and technical review processes (including WHO prequalification and SAGE recommendation) and meeting the financial assumptions used as the basis for the multivalent meningococcal vaccine investment case set out in Doc 08 Appendix 2.

Decision 4: Vaccine Investment Strategy (3/5)

- d) **Approved** a transition of the oral cholera vaccine programme to include a preventive immunisation programme with vaccine co-financing, beginning in 2021.
- e) **Approved** support for human rabies vaccine for post-exposure prophylaxis, beginning in 2021.
- f) **Approved:**
 - i. In principle, support for Respiratory Syncytial Virus (RSV) immunisation products, contingent on the availability of a licensed product, outcomes of regulatory and technical review processes (including WHO prequalification and SAGE recommendation), and meeting the financial assumptions used as the basis for the RSV investment case set out in Doc 08 Appendix 2.

Decision 4: Vaccine Investment Strategy (4/5)

- ii. Support beginning in 2019 for pre-introduction activities for RSV immunisation products including evidence and demand generation.

 - g) **Approved** the VIS learning agenda for 2019-2025 for D, T & P-containing booster vaccines, hepatitis B birth dose, ACW-containing multivalent meningococcal conjugate vaccines and human rabies vaccine for post-exposure prophylaxis, as described in Doc 08 Annex B.

 - h) **Noted** that the financial implications associated with the above conditional approvals for 2019-2020 are expected to be approximately US\$ 6.5 million, comprised of approximately US\$ 3 million in 2019 (which the Secretariat will strive to absorb from the Board-approved PEF budget for that year) and US\$ 3.5 million in 2020 for the VIS learning agenda for the vaccines described above and RSV introduction planning activities.
-

Decision 4: Vaccine Investment Strategy (5/5)

- i) **Noted** the financial implications associated with the above conditional approvals (taken as a whole) for 2021-2025 for vaccine and operational cost support are expected to be approximately US\$ 373 million, comprised of approximately US\$ 360 million for vaccine and operational cost support and approximately US\$ 13 million for the VIS learning agenda and RSV introduction planning activities.

Decision 5: Vaccine Investment Strategy (1/2)

The Gavi Alliance Board:

- a) **Approved** an extension of Gavi support for use of the global cholera stockpile in endemic settings for 2020, whereby components of the preventive immunisation programme are implemented beginning in 2019.
- b) **Authorised** the Secretariat, under the Programme Funding Policy, to (i) allot funding to the global cholera stockpile based on a financial forecast endorsed by the Board, (ii) allot funding to extend budgets to future years and/or (iii) adjust annual budget amounts as authorised by the CEO/DCEO taking into account updated timing of implementation and budget utilisation;

Decision 5: Vaccine Investment Strategy (2/2)

- c) **Approved** the VIS learning agenda activities for cholera for 2019-2025 as described in Doc 08 Annex B; and
- d) **Noted** that the financial implications associated with the above approvals for 2019-2020 are expected to be approximately US\$ 43.5 million, comprised of approximately US\$ 0.5 million in 2019 (which the Secretariat will strive to absorb from the Board-approved Partners' Engagement Framework (PEF) budget for that year) and US\$ 1 million in 2020 for the VIS learning agenda for cholera, and US\$ 42 million for extension of cholera support in 2020.

Decision 6: Approval of selected targets for 2016-2020 Strategic Indicators

The Gavi Alliance Board:

Approved targets for 2020 for three 2016-2020 Strategy Indicators: S2.1- Effective Vaccine Management, S2.5- Civil Society Engagement, S3.4- Institutional Capacity as set out in Section 2 of Annex B to Doc 09.

Decision 7: Consent agenda: Committee Charters

The Gavi Alliance Board:

- a) **Approved** the revised and updated Governance Committee Charter as set out in Annex A to Doc 10, effective from 1 January 2019;
- b) **Approved** the revised and updated Audit and Finance Committee Charter as set out in Annex B to Doc 10, effective from 1 January 2019;
- c) **Approved** the revised and updated Investment Committee Charter as set out in Annex C to Doc 10, effective from 1 January 2019; and
- d) **Approved** the revised and updated Programme and Policy Committee Charter as set out in Annex D to Doc 10, effective from 1 January 2019.

Decision 8: Consent agenda: Committee Chair appointments

The Gavi Alliance Board:

- a) **Reappointed** Helen Rees as an Unaffiliated Board member through to 30 June 2022; and
- b) **Appointed** Helen Rees as Chair of the Programme and Policy Committee effective 1 January 2019 through 31 December 2019.

Decision 9: Consent Agenda: Board/Committee members appointments (1/6)

The Gavi Alliance Board:

a) **Appointed** the following Board Members:

- **Harriet Ludwig** as Board Member representing Germany on the donor constituency anchored by Germany in the seat currently held by Jean-François Pactet of France effective 1 January 2019 and until 31 December 2019.
- **Harriet Pedersen** as Board Member representing Sweden on the donor constituency anchored by Norway in the seat currently held by Reina Buijs of the Netherlands effective 1 January 2019 and until 31 December 2020.
- **Sergey Khachatryan** of Armenia as Board Member representing the developing country constituency in the seat currently held by Edna Yolani Batres of Honduras effective 1 January 2019 and until 31 December 2021.

Decision 9: Consent Agenda: Board/Committee members appointments (2/6)

- **Aziz Mahamat Saleh** of Chad as Board Member representing the developing country constituency in the seat currently held by Raymonde Goudou Coffie of Côte d'Ivoire effective 1 January 2019 and until 31 December 2021.
- **Teresa Ressel** as an Unaffiliated Board Member in the seat formerly held by Gunilla Carlsson effective 1 January 2019 and until 31 December 2021.

b) **Appointed** the following Alternate Board Members:

- **Susan Elden** as Alternate Board member to Daniel Graymore representing the United Kingdom on the donor constituency anchored by the United Kingdom in the seat currently held by Jason Lane of the United Kingdom effective immediately and until 31 December 2019.

Decision 9: Consent Agenda: Board/Committee members appointments (3/6)

- **Jan Paehler** as Alternate Board member to Harriet Ludwig representing the European Commission on the donor constituency anchored by Germany in the seat currently held by Harriet Ludwig of Germany effective 1 January 2019 and until 31 December 2019.
- **Lene Lothe** as Alternate Board member to Harriet Pedersen representing Norway on the donor constituency anchored by Norway in the seat currently held by Karin Westerberg of Sweden effective 1 January 2019 and until 31 December 2020.
- **William Schluter** as Alternate Board member to Marta Nunes representing the research and technical health institutes constituency in the seat currently held by Kate O'Brien effective 1 January 2019 and until 31 December 2020.

Decision 9: Consent Agenda: Board/Committee members appointments (4/6)

- **Edna Yolani Batres** of Honduras as Alternate Board member to Sergey Khachatryan of Armenia representing the developing country constituency in the seat currently held by Sergey Khachatryan of Armenia effective 1 January 2019 and until 31 December 2021.
 - **Jacqueline Lydia Mikolo** of the Republic of Congo as Alternate Board member to Aziz Mahamet Saleh of Chad representing the developing country constituency in the seat currently held by Félix Kabange of the Democratic Republic of the Congo effective 1 January 2019 and until 31 December 2021.
- c) **Appointed** the following to the Market-Sensitive Decisions Committee effective 1 January 2019:
- **Jan Paehler** (Alternate Board Member) until 31 December 2019
 - **Helen Rees** (Board Member) until 31 December 2019

Decision 9: Consent Agenda: Board/Committee members appointments (5/6)

- d) **Reappointed** the following to the Governance Committee effective 1 January 2019:
- **Harriet Ludwig** (Board Member) until 31 December 2019
- e) **Appointed** the following to the Audit and Finance Committee effective 1 January 2019:
- **Teresa Ressel** (Board Member) until 31 December 2019
- f) **Appointed** the following to the Programme and Policy Committee effective immediately:
- **Susan Elden** (Alternate Board Member) until 31 December 2019

Decision 9: Consent Agenda: Board/Committee members appointments (6/6)

- g) **Reappointed** the following to the Programme and Policy Committee effective 1 January 2019:
- **Edna Yolani Batres** (Alternate Board Member) until 31 December 2019

Decision 10: Consent Agenda: Independent Review Committee appointments

The Gavi Alliance Board:

- a) **Appointed** as new IRC members the individuals listed in Annex A to Doc 10c for terms effective 1 January 2019 until 31 March 2021;
- b) **Approved** the extension of the terms of the IRC members listed in Annex B to Doc 10c for a further three-year term until 31 March 2022;
- c) **Approved** the exceptional extension of the term of Sandra Mounier-Jack as a member of the IRC pool until December 2019 so that she may serve out her term as IRC Vice Chair.

Decision 11: Consent Agenda: Review of Board Travel Policy

The Gavi Alliance Board:

Approved amendments to the Board Travel Policy as outlined in Annex A to Doc 10d.

Decision 12: Consent Agenda: CEO Authorisation to represent Gavi at IFFIm General Meeting

The Gavi Alliance Board:

Appointed Dr Seth Berkley, Gavi Alliance Chief Executive Officer, as the Gavi Alliance's authorised representative to attend, act and vote on its behalf at the General Meeting of the International Finance Facility for Immunisation Company (registered in the United Kingdom) provisionally scheduled to held at 14.00 (London time) on 17 December 2018 or on such other date and at such other time as may be determined by the IFFIm Board in its sole discretion.

Decision 13: Consent Agenda: Ongoing and planned support for Syria

The Gavi Alliance Board:

Approved extending 2017/2018 support for Syria approved by the Gavi Alliance Board in December 2016 for use in 2019.

Decision 14: Consent Agenda: Gavi supported measles and rubella immunisation activities: amendment to HSIS support framework

The Gavi Alliance Board:

Approved the following wording to be included as Annex B to Gavi's HSIS support framework

Annex B – Operational Cost Support for Measles Containing Vaccines

In order to encourage countries to strengthen routine immunisation for measles containing vaccines (MCV) and reach zero and one dose children, countries are able to apply for operational costs support for M/MR follow-up supplementary immunisation activities (SIAs) up to the national 9-59 month population, to be used for national SIAs, subnational SIAs and enhanced routine immunisation activities targeted at reaching missed children.

Decision 15: Consent Agenda: Post-transition plans for Angola and Timor-Leste and Congo Republic's eligibility for Gavi support

The Gavi Alliance Board:

- a) **Approved**, exceptionally, that the determination of Congo Republic's eligibility for 2019 will be based on the latest GNI data instead of the average GNI per capita over the past three years and to increase the HSS envelope to up to US\$ 10 million for a five year period;
- b) **Requested** the Secretariat to monitor the provision of domestic financing for vaccines in Congo Republic and report back to the Programme and Policy Committee and Board should challenges arise; and
- c) **Approved** within the overall Partners Engagement Framework an additional amount of up to US\$10 million for post-transition support for Angola and Timor-Leste for the period 2018-2023, bringing the total approved post-transition support to these countries up to US\$ 30 million.

Decision 16: Gavi's Support for Inactivated Polio Vaccine (IPV) post 2020 (1/3)

The Gavi Alliance Board:

- a) **Approved**, subject to the availability of funding for the 2021-2025 period following Gavi's replenishment for that period, support for inactivated poliovirus vaccine (IPV), with country financing arrangements subject to alignment with the final parameter setting for Gavi 5.0 at the June 2019 Board meeting;
- b) **Approved**, in-principle support for IPV containing whole-cell pertussis Hexavalent vaccine (Hexavalent) for the administration of IPV, diphtheria, tetanus, whole-cell pertussis, hepatitis B and Haemophilus influenza b antigens, subject to a vaccine being licenced, recommended for use by WHO, WHO pre-qualified and that market attributes support the successful implementation of Hexavalent;

Decision 16: Gavi's Support for Inactivated Polio Vaccine (IPV) post 2020 (2/3)

- c) **Noted** the importance of close collaboration between Gavi and the Global Polio Eradication Initiative (GPEI) and polio partners, including advocacy for future Gavi funding for IPV;

- d) **Requests** GPEI to include IPV post-2020 within its 2019-2023 programmatic strategy and reflect IPV associated costs as part of total estimated costs to achieve and sustain eradication; and

Decision 16: Gavi's Support for Inactivated Polio Vaccine (IPV) post 2020 (3/3)

- e) **Noted** that the financial implications associated with these decisions are expected to be up to US\$ 850 million (of which an estimated US\$ 848 million is dedicated to standalone IPV) for the period 2021-2025 and that, given that financing for IPV was not included in the investment case for the replenishment in 2015, funds for IPV support beyond 2020 would have to be considered as additional to other Gavi investments for Gavi 5.0, recognising full programmatic integration of IPV into Gavi's overall immunisation strengthening approach.

Decision 17: Pandemic Influenza Preparedness

The Gavi Alliance Board:

- a) **Approved** the development of a learning agenda to assess the feasibility and impact of routine influenza immunisation of healthcare workers to support epidemic and pandemic influenza preparedness;
- b) **Noted** the financial implications associated with the above approval for 2019-2022 are expected to be approximately US\$ 4 million, comprised of approximately US\$ 1 million in 2019 (which the Secretariat will strive to absorb from the Board-approved Partners' Engagement Framework (PEF) budget for that year), US\$ 1 million in 2020 and US\$ 2 million in 2021-2022.

Decision 18: Gavi Support for Yellow Fever Diagnostic Capacity (1/2)

The Gavi Alliance Board:

- a) **Approved** an amount of up to US\$ 8.2 million during 2019-2021 (of which US\$ 4.6 million would be for 2019-2020) for costs related to the procurement and distribution of laboratory reagents, supplies, and equipment for yellow fever diagnostic capacity strengthening through a diagnostic procurement mechanism based on Gavi's existing application, review, and approval processes;
- b) **Noted** the expected use of Partners' Engagement Framework (PEF) funds, estimated at approximately US\$ 5.3 million during 2019-2021, to support yellow fever diagnostic capacity strengthening; including technical assistance, quality assurance/quality control assessments, support for sample transportation, and coordination. The Gavi Secretariat will seek to absorb the 2019 estimated costs of US\$ 1.7 million within existing approved budgets;

Decision 18: Gavi Support for Yellow Fever Diagnostic Capacity (2/2)

- c) **Noted** the continued limited use of health systems strengthening (HSS) funds to support surveillance and laboratory capacity in the context of national plans that focus on achieving and maintaining high immunisation coverage and address underlying equity challenges; and
- d) **Requested** the Gavi Secretariat to report back to the PPC and Board on progress in 2019.

Decision 19: India's request for IPV support

The Gavi Alliance Board:

Approved, further to its decision on exceptional Gavi support for IPV from 2013 for Gavi eligible and graduating countries and the risks to the polio eradication agenda, the use of core resources (in an amount estimated at US\$ 40 million based on current projections) to support inactivated poliovirus vaccine (IPV) in India for the period 2019-2021.

Thank you



www.gavi.org